PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Paris:IPN) (Euronext: FR0010259150; IPN) today announced the results of phase I and Phase IIa clinical studies for its BIM23A760 designed and developed by Ipsen’s research team using its validated peptide engineering platform. BIM23A760 is a first-in-class innovative “chimeric” compound that bears within a single molecule two pharmacological moieties, i.e. a somatostatin analog and a dopamine agonist. This molecule targets two of the most commonly patho-physiological pathways associated with pituitary tumours: growth hormone and prolactin. The design of BIM23A760 is based on a novel concept in molecular biology regarding the amplification of intracellular signalling when engaging simultaneously two receptors with their respective ligands.
